Compare iShares MSCI Indonesia ETF (EIDO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.2, while Recursion Pharmaceuticals Inc trades at $3.17 (market cap $1.75B). Which is the better fit depends on your goals.
| EIDO | RXRX | |
|---|---|---|
52-Week High | $19.22 | $6.79 |
52-Week Low | $10.80 | $2.84 |
Market Cap | — | $1.75B |
Sector | — | Health |
Enterprise Value | — | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.20, up 1.08% on the day, while technical indicators signal a bearish trend with moving averages and overall signals in sell territory. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah, which directly impacts this country-focused ETF. The fund's dividend was reported to have dropped 27% in 2025, raising questions about underlying asset performance.
The outlook for EIDO is tied to Indonesia's macroeconomic stability and government policy execution. Investment opportunity lies in exposure to Indonesia's growth initiatives, but risks include currency volatility from Bank Indonesia's defensive actions, geopolitical pressures on emerging markets, and the ETF's high-yield but potentially unstable dividend profile.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
